Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | CD38 | P28907 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927616 | 0.80 | PARP1 (0.60) | PARP1DHODHRPS6KB1CHEK2 | |
| SCHEMBL29179987 | 0.79 | PARP1 (0.74) | PARP1DHODHRPS6KB1HDAC3HDAC1 | |
| SCHEMBL30225827 | 0.79 | PARP1 (0.57) | PARP1 | |
| SCHEMBL30811242 | 0.78 | PARP1 (0.77) | PARP1DHODHRPS6KB1PARP2CHEK2 | |
| SCHEMBL29179975 | 0.78 | PARP1 (0.77) | PARP1DHODHRPS6KB1PARP2CHEK2 | |
| SCHEMBL6842025 | 0.78 | PARP1 (0.66) | PARP1DHODHRPS6KB1PARP2CHEK2 | |
| SCHEMBL6102487 | 0.77 | DHODH (0.51) | PARP1DHODHRPS6KB1PARP2CHEK2 | |
| SCHEMBL8211452 | 0.77 | HDAC6 (0.57) | TP53RAB9ASMN1; SMN2CD38RPS6KB1 | |
| SCHEMBL29412049 | 0.76 | PARP1 (0.60) | PARP1RAB9ADHODHCHEK2 | |
| SCHEMBL6841123 | 0.76 | PIM1 (0.61) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | AGOURON PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | PARP1, PARP11, PARP2 | PARP1 1/4885TP53 528/4885RAB9A 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.